(TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune systems. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we believe we are the only company developing bispecific gamma-delta T cell engaging antibodies for the treatment of cancer.